- AustraliaNorth AmericaWorld
Investing News NetworkYour trusted source for investing success
Silver47 Exploration
Purpose Bitcoin ETF
Jindalee Lithium
Black Swan Graphene
- Lithium Outlook
- Oil and Gas Outlook
- Gold Outlook Report
- Uranium Outlook
- Rare Earths Outlook
- All Outlook Reports
- Top Generative AI Stocks
- Top EV Stocks
- Biggest AI Companies
- Biggest Blockchain Stocks
- Biggest Cryptocurrency-mining Stocks
- Biggest Cybersecurity Companies
- Biggest Robotics Companies
- Biggest Social Media Companies
- Biggest Technology ETFs
- Artificial Intellgience ETFs
- Robotics ETFs
- Canadian Cryptocurrency ETFs
- Artificial Intelligence Outlook
- EV Outlook
- Cleantech Outlook
- Crypto Outlook
- Tech Outlook
- All Market Outlook Reports
- Cannabis Weekly Round-Up
- Top Alzheimer's Treatment Stocks
- Top Biotech Stocks
- Top Plant-based Food Stocks
- Biggest Cannabis Stocks
- Biggest Pharma Stocks
- Longevity Stocks to Watch
- Psychedelics Stocks to Watch
- Top Cobalt Stocks
- Small Biotech ETFs to Watch
- Top Life Science ETFs
- Biggest Pharmaceutical ETFs
- Life Science Outlook
- Biotech Outlook
- Cannabis Outlook
- Pharma Outlook
- Psychedelics Outlook
- All Market Outlook Reports
Ceapro shared its financial results for the second quarter of 2017 and gave a business update to shareholders.
Ceapro (TSXV:CZO) shared its financial results for the second quarter of 2017 and gave a business update to shareholders.
As quoted in the press release:
“This positive past quarter was highlighted by continued investments in our technologies as well as accelerated R&D investments in our product pipeline as a step toward our long-term goal of transforming Ceapro from a manufacturing company to a full-fledged biopharmaceutical company. On a short-term basis, we are working to maintain and expand our base business in cosmeceuticals, which provides us with the financial security to position ourselves for our contemplated transition into large potential markets in nutraceuticals and pharmaceuticals with our value drivers avenanthramides and beta glucan,” stated Gilles Gagnon, M.Sc., MBA, President and CEO of Ceapro “Over the course of 2017 we have been assessing different marketing scenarios with the intention of increasing our market share in cosmeceuticals and restoring the market for beta glucan, which has been mainly responsible for the difference in sales observed between the first six months of 2017 and 2016. New applications and market channels are being developed.”
“Additionally, we expect to see continued growth in our avenanthramides program as we anticipate new products to be launched by major customers over the next twelve months utilizing our avenanthramides in variety of products, mostly in haircare. We also keep our eyes and ears open for any potential and affordable accretive acquisition to accelerate our entry into the nutraceuticals market,” Mr. Gagnon added.
Click here to read the full press release.
Source: www.marketwired.com
Latest News
Investing News Network websites or approved third-party tools use cookies. Please refer to the cookie policy for collected data, privacy and GDPR compliance. By continuing to browse the site, you agree to our use of cookies.